Skip to main content

Advertisement

Table 3 Adverse Events in Pazopanib Recipients by Number of Prior Lines of Therapy (Safety Population)

From: Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

Events, n (%) 1 prior line (n = 109) 2+ prior lines (n = 131)
Any on-therapy AE 108 (> 99) 129 (98)
AEs related to study treatment 101 (93) 118 (90)
AEs leading to permanent discontinuation or early withdrawal 24 (22) 24 (18)
AEs leading to dose reduction 38 (35) 39 (30)
AEs leading to dose interruption/delay 59 (54) 61 (47)
Any SAE 47 (43) 52 (40)
SAEs related to study treatment 26 (24) 31 (24)
Fatal SAEs 5 (5) 3 (2)
Fatal SAEs related to study treatment 0 (0) 1 (< 1)
  1. AE adverse event, SAE serious adverse event.